A Third Drug for a Stent That Won't Be In Much Longer
A man on chronic tamsulosin for his prostate now has stent pain from an unrelated stone surgery. The question isn't which drug beats placebo — it's whether a second drug earns its place on top of the one he's already taking.
Walter K., a 52-year-old man, has taught auto shop at the same high school for twenty-two years, and spent Tuesday afternoon walking a sophomore through a brake job one-handed because his right flank wouldn't let him bend under the lift. Three days earlier he'd had ureteroscopy and laser lithotripsy for an 8mm proximal ureteral stone, with a double-J stent left in place until his removal appointment in eleven days. He has mild BPH — nocturia twice a night, a weak stream he'd mostly stopped noticing — managed for the past four years on tamsulosin 0.4mg, which he takes every night before bed and has no intention of stopping. Since the stent went in, that same flank has developed a new, different discomfort: a dragging ache with each void, urgency that gets him up if he even thinks about a full bladder, and enough intermittent colic that he's been taking his prescribed acetaminophen/oxycodone on a schedule rather than as needed.
The pharmacologic question isn't whether an alpha-blocker helps stent symptoms in general — Walter is already living proof it does something, or at least does no harm, since he's tolerated tamsulosin for years without note. The real question is what, if anything, to add on top of it. Xiang et al.'s 2024 network meta-analysis, pooling sixteen trials and 2,002 patients, found mirabegron, tamsulosin, and solifenacin all outperformed placebo on the USSQ urinary-symptom domain, with no significant separation among the three drugs themselves — solifenacin ranked highest by SUCRA at 73.1%, but mirabegron sat at 72.9% on an identical mean rank, which is a difference too small to prescribe on. The same analysis is far less equivocal about harm: solifenacin alone carried a statistically significant excess of adverse events against placebo (RR 3.70, 95% CI 1.38–9.90), ranking last of the three on tolerability, while mirabegron ranked first on both body pain and adverse events. None of those sixteen trials, notably, enrolled a background-tamsulosin population; they tested each drug against no drug, not against "more drug" in someone already on one.
Stent clinic, three days in
Eleven days is long enough for stent-related pain to genuinely erode someone's week, and the largest synthesis we have — Xiang's 2024 network meta-analysis, sixteen randomized trials and two thousand patients — found solifenacin carried the highest probability of being the single best agent for USSQ urinary-symptom relief, ahead of both mirabegron and tamsulosin alone. I'd add it to what he's already taking.
The mechanism argument for adding it on top of his tamsulosin is clean: alpha-blockade handles smooth-muscle tone, an antimuscarinic handles the detrusor overactivity a stent's bladder-end coil provokes directly. They're not doing the same job.
You're right that solifenacin ranked highest on SUCRA — but SUCRA measures probability of being best among three drugs that all beat placebo, and the trial's own confidence intervals for all three overlap enough that "ranked first" isn't the same as "proven better." None of the sixteen trials in that pool enrolled a man already on a background alpha-blocker, so we're extrapolating either way.
And I'd point out that the same analysis you're ranking solifenacin from is the one that measured its cost: solifenacin was the only one of the three with a statistically significant excess of adverse events against placebo, RR 3.70, and it finished last of the three on tolerability. That isn't my theoretical worry about stacking an antimuscarinic on an alpha-blocker in a man with even mild BPH — it's a number from your own source.
Tae et al.'s multicentre randomized study is the better fit for what he's actually complaining of: USSQ body-pain scores of 13.96 against 21.96 in untreated controls, and overall pain 2.83 against 5.58. Pain, not frequency, is what has him on scheduled oxycodone.
Both of you are reading real findings, and neither of you is wrong about what's in the literature. What I'd push back on is the premise that adding something is the default and the burden is on showing why not to. The same network meta-analysis that ranked solifenacin first also found no statistically significant separation among mirabegron, tamsulosin, and solifenacin themselves — the clear signal is drug beats placebo, not drug A beats drug B.
His stent comes out in eleven days. That's the actual clinical fact this decision has to answer to: whatever we start, we're starting it for a fixed, short window, against a literature base that's mostly small, single-center trials with real heterogeneity in dose, duration, and population.
I don't think the honest answer is nothing, given how much this is actually bothering him at work. I think it's mirabegron, specifically because it targets his stated complaint — pain, not just urinary frequency — without stacking a second lower-urinary-tract drug against tamsulosin, and we watch him closely rather than reaching for a second agent if it doesn't help by his removal appointment.
Agreed: start mirabegron 50mg daily, continue tamsulosin unchanged, reassess at his stent-removal appointment in eleven days rather than mid-interval unless the pain escalates. If mirabegron doesn't meaningfully help within a week, the plan is to stop it rather than add solifenacin on top — the group was explicit that escalating to a second added agent isn't justified by evidence this inconsistent.
Not agreed: the Primary Care Physician's underlying view that nothing should have been added at all, given how thin and heterogeneous the trial base really is, wasn't overruled so much as outweighed by Walter's own report of how much the pain was actually costing him day to day. That tension — a real symptom against genuinely uncertain evidence — was named directly rather than smoothed over.